Cross Neutralization of Afro-Asian Cobra and Asian Krait Venoms by a Thai Polyvalent Snake Antivenom (Neuro Polyvalent Snake Antivenom)

Poh Kuan Leong¹, Si Mui Sim¹, Shin Yee Fung², Khomvilai Sumana³, Visith Sitprija³, Nget Hong Tan²*

¹ Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, ² CENAR and Department of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, ³ Queen Saovabha Memorial Institute, Bangkok, Thailand

Abstract

Background: Snake envenomation is a serious public health threat in the rural areas of Asian and African countries. To date, the only proven treatment for snake envenomation is antivenom therapy. Cross-neutralization of heterologous venoms by antivenom raised against venoms of closely related species has been reported. The present study examined the cross-neutralizing potential of a newly developed polyvalent antivenom, termed Neuro Polyvalent Snake Antivenom (NPAV). NPAV was produced by immunization against 4 Thai elapid venoms.

Principal Findings: In vitro neutralization study using mice showed that NPAV was able to neutralize effectively the lethality of venoms of most common Asian cobras (Naja spp.), Ophiophagus hannah and kraits (Bungarus spp.) from Southeast Asia, but only moderately to weakly effective against venoms of Naja from India subcontinent and Africa. Studies with several venoms showed that the in vivo neutralization potency of the NPAV was comparable to the in vitro neutralization potency. NPAV could also fully protect against N. sputatrix venom-induced cardio-respiratory depressant and neuromuscular blocking effects in anesthetized rats, demonstrating that the NPAV could neutralize most of the major lethal toxins in the Naja venom.

Conclusions/Significance: The newly developed polyvalent antivenom NPAV may find potential application in the treatment of elapid bites in Southeast Asia, especially Malaysia, a neighboring nation of Thailand. Nevertheless, the applicability of NPAV in the treatment of cobra and krait envenomations in Southeast Asian victims needs to be confirmed by clinical trials. The cross-neutralization results may contribute to the design of broad-spectrum polyvalent antivenom.

Introduction

The global figure of snake envenoming cases has been estimated to be greater than 1.8 million annually, with an annual death toll of more than 90,000. The predominant envenoming species occurs in South Asia and Southeast Asia (estimated 720,000 cases, 53,000 fatalities), followed by Africa (estimated 420,000 cases, 32,000 fatality) [1], and the main biting species are snakes from the Elapidae and Viperidae families. Among members of the Elapidae family, the cobras and kraits are the main causes of snake envenoming [2,3]. There are about 34 species of cobras belonging to 7 genera (Acestelaps, Boulengerina, Hemachatus, Naja, Ophiophagus, Pseudechis and Waihtannesia). The genus Naja distributed extensively across large regions of the Africa (13 species) and Asia (12 species) [4]. Ophiophagus hannah or commonly known as the king cobra, is the only member of the Ophiophagus genus and is found only in Asia. Bungarus (the kraits), are represented by 12 species and their distribution is confined to the Indian subcontinent, Southeast Asia, as well as Southern China and Taiwan [4]. Cobra and krait envenomations are generally characterized by neurotoxic envenoming [5].

Antivenom therapy is the only effective treatment for snake envenomation. Monovalent antivenoms are raised with venom from one particular species and hence generally only effective in the treatment of envenomation caused by the particular species. Because of the difficulties in accurate diagnosis of the biting species, polyvalent antivenoms that offer paraspecific protection against several venomous snake bites have also been developed and become commercially available. It has been argued that monovalent antivenoms are generally more effective than polyvalent antivenoms, though this has not been firmly established. At present, several types of polyvalent antivenoms against Afro-Asian venomous snakes are available in the market, produced mainly by Asian or African commercial pharmaceutical firms or government institutions [5,6]. There is, however, a lack of rigorous evaluation of the paraspecific protective actions of these commercially available polyvalent antivenoms. Recently, Thai Red Cross Society produced a new polyvalent antivenom that offers...
**Author Summary**

Snake envenomation is a serious public health threat in the rural areas of Asia and Africa. To date, the only proven treatment for snake envenomation is antivenom therapy. Owing to the difficulties in the diagnosis of the biting species, there is a need to develop polyvalent antivenoms that could cross-neutralize venoms of medically important venomous snakes in the various regions. Recently, Thai Red Cross Society from Thailand has developed a new polyvalent antivenom for treatment of cobra and krait venoms. The polyvalent antivenom, termed “Neuro Polyvalent Snake Antivenom (NPAV),” is raised against venoms of two Thai cobras and two Thai kraits. Our results indicated that the polyvalent antivenom can effectively neutralize venoms from many Southeast Asian cobras, kraits and king cobra but is less effective against Indian cobra venoms. Studies using anesthetized rats showed that NPAV can effectively protect against cobra venom-induced cardio-respiratory depressant and neuromuscular blocking effects, confirming that the antivenom can effectively neutralize the major lethal toxins of common cobra venoms. This new antivenom may find potential application in the treatment of elapid bites in Southeast Asia, especially Malaysia, a neighboring nation of Thailand.

**Materials and Methods**

**Venoms and antivenoms**

Venoms of *Naja sputatrix*, *Naja siamensis*, *Naja kaouthia* (Thailand), *Naja philippinensis*, *Naja oxiana*, *Naja atra*, *Naja naja* (Sri Lanka, sample 1), *Naja naja* (India, sample 1 and 2), *Naja melanoleuca*, *Naja nigricollis*, *Naja nubiae*, *Naja katemisi*, *Naja haje*, *Bungarus multicinctus* and *Bungarus caeruleus* were purchased from Latoxan (Valence, France). Venoms of *Naja sumatrana*, *Naja kaouthia* (Malaysia), *Ophiophagus hannah*, *Bungarus candidus*, *Bungarus fasciatus* and *Bungarus flaviceps* were pooled samples obtained from several adult individuals captured in Malaysia whilst *Naja naja* (Sri Lanka sample 2) was a pooled sample obtained from several adult individuals captured in Sri Lanka. After extraction, the venoms were instantly lyophilized. Two antivenoms were purchased from Latoxan (Valence, France). Venoms and antivenoms were reconstituted in the same manner: 10 mL of normal saline was added to 1 vial of the freeze-dried antivenom. According to the attached fact sheet, 1 mL of the NPAV antivenom is able to neutralize the following amount of snake venoms: 0.6 mg each of *N. kaouthia* and *B. fasciatus* venoms, 0.4 mg of *B. candidus* and 0.8 mg of *O. hannah* venoms; while 1 mL of the NKMAV can neutralize 0.6 mg of *N. kaouthia* venom.

**Animals**

Albino mice (ICR strain, 20–25 g) and male Sprague Dawley rats (250–300 g) were supplied by the Laboratory Animal Centre, Faculty of Medicine, University of Malaya. The animals were handled according to the guidelines given by CIOMS on animal experimentation [9]. All experiments involving animals were approved by the Animal Care and Use Committee (ACUC) of the University of Malaya (Ethical clearance letter No. PM/05/03/ 2010/FSY[R]).

**Determination of protein content**

Protein content was determined by Bradford method [9]. All measurements were performed in triplicate. Bovine serum albumin (Sigma, USA) was used to generate a standard curve.

**Chromatographic and electrophoretic profiling of the antivenom**

SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was conducted according to the method of Studier [10], using the Bio-Rad broad-range prestained SDS-PAGE standards (6.5–200 kDa) and 15 μL of each antivenom sample (3 mg/mL) was loaded in the gel (12.5%). High performance gel filtration chromatography of the reconstituted antivenom (100 μL, 10 mg/mL) was performed using a Superdex 200 HR 10/30, 13 μm SEC 10×300 mm (GE Healthcare, Sweden). Elution buffer was 100 mM sodium phosphate, 0.15 M NaCl, pH 7.4 at a flow rate of 0.75 mL/min. Protein was monitored by absorbance measurement at 280 nm. The column was calibrated using the following protein standards obtained from Bio-Rad (BIO-RAD Gel filtration Standard): thyroglobulin (670 kDa), γ-globulin (150 kDa), ovalbumin (44 kDa) and myoglobin (17 kDa).

**Determination of venom lethality**

The median lethal dose, LD$_{50}$, of the venom was determined by intravenous or intramuscular injection into ICR mice (20–25 g, n = 4). The survival ratio was recorded after 48 h to determine the LD$_{50}$.

**In vitro neutralization of lethality of venoms**

In vitro neutralization of lethality was conducted as described by Ramos-Cerrillo et al. [11]. Briefly, a challenge dose of the venom in 50 μL saline was pre-incubated at 37 °C for 30 min with various dilutions of the reconstituted antivenom (NPAV or NKMAV) in normal saline, to give a total volume of 250 μL. The mixture was subsequently centrifuged at 10000×g before being injected into the caudal vein of the mice. The number of survival after 48 h was recorded. Generally, the challenge dose used was 5 LD$_{50}$. However, if 200 μL of the reconstituted antivenom (maximum permitted volume to inject into the mouse) failed to give full protection of the mice, a lower challenge dose of 2.5 LD$_{50}$ was
used instead. The antivenom was considered ineffective when none of the animals injected with the pre-incubated mixture (containing 2.5 LD_{50} challenge venom in 50 μL saline and 200 μL of the undiluted reconstituted antivenom) survived. Neutralizing potency of the antivenom was expressed as ED_{50} (the amount of reconstituted antivenom in μL or the ratio of mg venom/mL reconstituted antivenom that gives 50% survival of the animals tested) as well as in term of ‘neutralization potency’ (P, the amount of venom that is completely neutralized by a unit volume of antivenom) calculated according to Morais et al. [12].

**In vivo neutralization of lethality of venom**

This was carried out by intramuscular injection of 5 LD_{50} or 2.5 LD_{50} of the venom into mice (n = 4) followed by intravenous injection of 200 μL of appropriately diluted reconstituted antivenom, 10 min later. The number of survival after 48 h was recorded.

Protective actions of the antivenom against *N. sputatrix* venom-induced cardiovascular depressant and neuromuscular blocking effects in anesthetized rats

The study was conducted on three groups of rats (n = 3, 250–300 g) anesthetized with intraperitoneal injection of urethane (1.4 g/kg, i.p.) to the point of loss of the eyelid reflex and the pedal withdrawal reflex on painful stimuli. The anesthetized animals were surgically prepared for the simultaneous measurement of blood pressure, heart rate, respiratory rate and muscle twitch tension. Data collection and analysis were conducted using PowerLab 4/30 data acquisition system equipped with LabChart software (AD Instruments, Australia). Rats in group 1 (termed ‘saline/’-’ group) were injected with 50 μL saline intramuscularly at 0 min and served as control; Rats in group 2 (termed ‘NsV/-’ group) were injected with 6 mg/kg *N. sputatrix* venom (dissolved in 50 μL saline) intramuscularly; and rats in group 3 (termed ‘NsV/ NPAV’ group) were injected with the same dose of venom intramuscularly followed by intravenous administration of 3 mL of the reconstituted NPAV (1 mL each at 10 min, 30 min and 50 min post-injection of the venom). The volume of antivenom administered and the time points were chosen to ensure no disturbance of the blood pressure, heart rate and respiratory rate occurred.

**Statistical analysis**

LD_{50} of the venoms and ED_{50} of antivenoms are expressed as means with 95\% confidence intervals (C.I.); LD_{50}, ED_{50} (median effective dose) and the 95\% confidence intervals (C.I.) were calculated using the probit analysis method of Finney [13] with the BioStat 2009 analysis software (AnalystSoft Inc.). The statistical analysis for pharmacological study was conducted using SPSS. The data (expressed as mean ± S.D.) were analyzed using one-way ANOVA, with Tukey’s post hoc multiple-comparison test, with P<0.05 as significant.

**Results**

Composition of the antivenoms

The protein contents of reconstituted NPAV and NKMAV were 20.3 mg/mL and 12.5 mg/mL, respectively. The SDS-PAGE patterns of NPAV (Neuro Polyvalent Snake Antivenom) and NKMAV (*Naja kaouthia* monovalent antivenom) indicated that there was no distinct band of high or low molecular weight proteins (Fig. 1). The same was also observed in the gel-filtration chromatographic profiles of the two antivenoms (Fig. 2). Based on ‘area-under-the-curve’ comparison, the quantity of F(ab’)_2 in both these antivenoms were comparable (91–96\%) whilst the quantity of respective dimers and low molecular weight proteins in NKMAV were slightly higher than those in NPAV (Fig 2). No high molecular weight aggregates were detected in both of these antivenoms.

**In vitro neutralization of venom lethal effects by the antivenoms**

The results of the *in vitro* neutralization of venom lethality by the NPAV and the monovalent *N. kaouthia* antivenom (only for selected venoms) are shown in Table 1 and 2, respectively. The results showed that NPAV was able to confer protection/cross-protection against the venoms of all krait as well as almost all the Afro-Asian cobra venoms examined (except for the African spitting cobra *N. katensis*), although the neutralizing potency range varied from low to high. The NKMAV was able to neutralize the venoms of six Asian cobras (*N. kaouthia* [Thailand & Malaysia], *N. spurttrix*, *N. sumatrana*, *N. siamensis* and *O. hannah*) tested, with efficacy comparable to that of NPAV, but failed to neutralize the venoms of *B. fasciatus* and *B. candidus*. It is interesting to note that our results

![Figure 1. SDS-PAGE of Neuro Polyvalent Snake Antivenom (NPAV) and *Naja kaouthia* monovalent antivenom (NKMAV).](doi:10.1371/journal.pntd.0001672.g001)
on the neutralization potentials of NPAV against *N. kaouthia*, *B. fasciatus*, *B. candidus* and *O. hannah* venoms are much higher than stated in the antivenom fact sheet provided, in particular against *O. hannah* venom. It should be noted, however, that the definition of neutralization potential used in the fact sheet has not been clearly stated.

**Table 1. In vitro neutralization of lethality of Afro-Asian cobra and krait venoms by NPAV.**

| Venom                | i.v. LD$_{50}$ (mg/g) | Challenge dose | NPAV ED$_{50}$ (μL) | ED$_{50}$ in mg/mL | P (mg/mL) |
|----------------------|------------------------|----------------|----------------------|---------------------|------------|
| *Naja sputatrix*     | 0.90 (0.59–1.36)       | 5 LD$_{50}$   | 111.25               | 0.93 (0.61–1.41)    | 0.74       |
| *Naja siamensis*     | 0.28 (0.18–0.42)       | 5 LD$_{50}$   | 22.47                | 1.43 (0.94–2.18)    | 1.15       |
| *Naja sumatrana*     | 0.50 (0.40–0.62)       | 5 LD$_{50}$   | 25.00                | 2.30 (1.86–2.85)    | 1.84       |
| *Naja kaouthia* (Thailand) | 0.23 (0.15–0.34)   | 5 LD$_{50}$   | 22.47                | 1.18 (0.76–1.79)    | 0.94       |
| *Naja kaouthia* (Malaysia) | 0.89 (0.59–1.35)   | 5 LD$_{50}$   | 150.00               | 0.68 (0.62–0.75)    | 0.55       |
| *Naja philipinensis* | 0.18 (0.12–0.27)       | 5 LD$_{50}$   | 156.57               | 0.13 (0.11–0.16)    | 0.10       |
| *Naja atra*          | 0.56 (0.37–0.84)       | 2.5 LD$_{50}$ | 56.00                | 0.86 (0.79–0.94)    | 0.52       |
| *Naja oxiana*        | 1.11 (0.73–1.69)       | 2.5 LD$_{50}$ | 37.50                | 1.70 (1.56–1.85)    | 1.01       |
| *Naja naja* (India 1)| 1.80 (1.18–2.73)       | 2.5 LD$_{50}$ | 200.00               | 0.52                | 0.31       |
| *Naja naja* (India 2)| 1.08 (0.71–1.64)       | 2.5 LD$_{50}$ | 156.57               | 0.40 (0.32–0.49)    | 0.24       |
| *Naja naja* (Sri Lanka 1)| 1.13 (0.54–2.38)  | 2.5 LD$_{50}$ | 100.00               | 0.65 (0.52–0.84)    | 0.39       |
| *Naja naja* (Sri Lanka 2)| 1.08 (0.71–1.64)  | 5.0 LD$_{50}$ | 89.88                | 1.39 (0.91–2.08)    | 1.11       |
| *Naja haje*          | 0.09 (0.05–1.40)       | 2.5 LD$_{50}$ | 78.29                | 0.13 (0.11–0.16)    | 0.10       |
| *Naja melanoleuca*   | 0.33 (0.22–0.51)       | 5.0 LD$_{50}$ | 55.63                | 0.68 (0.44–1.03)    | 0.54       |
| *Naja nigricollis*   | 0.75 (0.69–0.82)       | 2.5 LD$_{50}$ | 55.63                | 0.78 (0.49–1.18)    | 0.47       |
| *Naja nubiae*        | 0.28 (0.22–0.37)       | 5.0 LD$_{50}$ | 78.29                | 0.41 (0.34–0.50)    | 0.33       |
| *Naja katiensis*     | 1.20 (0.97–1.45)       | 2.5 LD$_{50}$ | NE                   | NE                  | NE         |
| *Ophiophagus hannah* | 1.00 (0.81–1.24)       | 5.0 LD$_{50}$ | 11.24                | 10.23 (6.74–15.54)  | 8.19       |
| *Bungarus fasciatus* | 1.67 (1.10–2.53)       | 5.0 LD$_{50}$ | 111.25               | 1.73 (1.14–2.62)    | 1.38       |
| *Bungarus candidus*  | 0.11 (0.07–0.17)       | 5.0 LD$_{50}$ | 13.91                | 0.91 (0.60–1.38)    | 0.73       |
| *Bungarus flaviceps* | 0.175 (0.09–0.21)      | 5.0 LD$_{50}$ | 11.24                | 1.84 (1.21–2.80)    | 1.47       |
| *Bungarus multicinctus* | 0.11 (0.05–0.22)   | 5.0 LD$_{50}$ | 37.50                | 0.34 (0.31–0.37)    | 0.27       |
| *Bungarus caeruleus* | 0.17 (0.11–0.25)       | 5.0 LD$_{50}$ | 78.29                | 0.12 (0.10–0.15)    | 0.07       |

For LD$_{50}$ and ED$_{50}$, values in brackets are 95% CI.
2.5 or 5.0 LD$_{50}$ of venom in 50 μL was premixed with 200 μL of NPAV (Neuro Polyvalent Snake Antivenom) and incubated for 30 min. The mixture was then injected into mice (n = 4, 20–25 g) and monitored for 48 h. NE: Not effective at maximum volume of antivenom (200 μL) permitted.
*: estimated value, as the maximum volume of antivenom (200 μL) only achieved 50% protection of the animals.

doi:10.1371/journal.pntd.0001672.t001
In vivo neutralization of lethal effects of some Asian cobra and krait venoms

Table 3 shows the *in vivo* neutralization of lethality of four venoms from Asian cobras and krait (*N. sputatrix*, *N. kaouthia* (Thailand), *N. kaouthia* (Malaysia) and *B. candidus*) by NPAV. It is interesting to note that the *i.v.* LD$_{50}$ values determined were comparable to the corresponding *i.m.* LD$_{50}$ values. Our results showed that NPAV effectively neutralized all four venoms *in vivo*, with ED$_{50}$ comparable to the corresponding ED$_{50}$ in the *in vitro* neutralization assays.

The protective effects of NPAV on the *N. sputatrix* venom-induced cardio-respiratory depressant and neuromuscular blocking effects in the anesthetized rats

Figure 3 shows that NPAV was able to fully protect against the *N. sputatrix* venom-induced cardio-respiratory depressant and neuromuscular blocking effects in the anesthetized rats. The mean blood pressure (BP), heart rate, respiratory rate and muscle twitch tension of the control anesthetized rats (*saline/-* group) remained constant for at least 6 hours after the initial stabilization. Following an intramuscular injection of the venom at 4×LD$_{50}$ dose (6 mg/kg), however, there was an immediate small decrease (about 20%) in the BP, which remained constant thereafter for the next 90 min (Figure 3A). During this period, the heart rate remained essentially unaffected (Figure 3B). And then the BP and heart rate both began to fall precipitously from 90 min onward. On the other hand, the respiratory rate and muscle twitch tension were stable only for the first 60 min after venom administration. Both these parameters, however, began to decrease sharply thereafter (Figure 3C and 3D) and death occurred at 125–130 min after the venom injection.

In a parallel series of experiment conducted to examine the ability of NPAV to protect against the cardiovascular depressant and neuromuscular blocking effects of *N. sputatrix* venom, 1 mL each of NPAV was administered via the left jugular vein, at 10, 30 and 50 min, respectively, following the *i.m.* injection of the venom. The heart rate and muscle twitch tension of the antivenom-treated animals (*NsV/NPAV* group) were restored to the same levels as the *saline/-* control group (*P*<0.05, not significantly different between *saline/-* group and *NsV/NPAV* group by one-way ANOVA), whereas the blood pressure and respiratory rate were restored to 80% of the control group (*P*<0.05 between the two groups) and remained at that level throughout the monitoring period.

Discussion

Expression of neutralization capabilities of antivenom

In this report, the neutralization capabilities of the antivenoms are expressed in three different ways: the commonly used median effective dose ED$_{50}$ in μL antivenom, ED$_{50}$ in mg/mL antivenom and potency, P, as defined by Morais et al. [12]. For ED$_{50}$, expressing the value in term of mg venom neutralized per mL antivenom is a more realistic assessment of the neutralization capabilities of the antivenom than in term μL antivenom or number of mouse LD$_{50}$, because the LD$_{50}$'s of the various cobra venoms differ substantially. For example, expressed in term of μL antivenom, the ED$_{50}$'s of NPAV against *N. kaouthia* (Malaysia) venom and *N. philippinensis*
venom are comparable, but when expressed in term of mg/mL, NPAV was obviously much more effective against *N. kaouthia* (Malaysia) venom then against *N. philippinensis* venom.

Because of the high lethality of certain venoms, a 2.5 LD\textsubscript{50} instead of the standard 5 LD\textsubscript{50} was used as the challenge dose. Since the ED\textsubscript{50} value of an antivenom is highly dependent on the challenge dose, ED\textsubscript{50} obtained from the two different challenge doses cannot be compared directly. As such, we also expressed neutralization capability of the antivenom in terms of P (potency), which is the mass of venom that is completely neutralized per unit volume of antivenom, as defined by Morais et al. [12]. Potency gives a better estimate of the relative efficacy of antivenoms than comparing ED\textsubscript{50} values when different challenge doses were used in the determination of ED\textsubscript{50}, as P is theoretically independent of the amount of challenge doses. Nevertheless, since the relationship between antivenom neutralizing capability versus venom challenge dose is not necessarily true [14,15]. Our results here demonstrated that the quality and neutralization capabilities of polyvalent antivenom are not necessary inferior to that of monovalent antivenoms. Here we compared the protein composition of the *N. kaouthia* monovalent antivenom (NKMAV) and Neuro Polyvalent Snake Antivenom (NPAV), as well as the in vitro neutralization potency of the two antivenoms against venoms from five common Asiatic cobras and *O. hannah* (Table 2). The results show that both antivenoms are devoid of high molecular weight aggregates, the compounds that are usually associated with adverse reactions. The protein contents of the two antivenoms are both relatively low (20.3 mg/mL and 12.5 mg/mL respectively, for NPAV and NKMAV). The neutralization potencies of NKMAV and NPAV against *N. kaouthia* (Thailand) venom (the venom used to raise both antivenoms) are essentially the same. This, however, is not surprising since according to the manufacturer, monovalent antivenoms (including NKMAV) were later added to the purified polyvalent antivenom to ensure the neutralizing potency of the NPAV was comparable with the neutralizing potencies of the respective monovalent antivenoms. What is interesting is that, the neutralization potencies of both antivenoms against four Asiatic cobra venoms tested are comparable. NPAV, however, is much more potent than NKMAV in neutralizing *O. hannah* venom. This is to be expected as *O. hannah* venom was included in the immunogen mixture used in raising NPAV. These observations are in accordance with the conclusion drawn by Raweerith and Ratanabanangkoon [15].

**Comparison of monovalent antivenoms versus polyvalent antivenoms**

The relative merit of monovalent antivenoms versus polyvalent antivenoms has been the subject of much discussion [14] and there are some authors who suggested that monovalent antivenoms are generally more potent than polyvalent antivenoms and less likely to cause adverse reactions as it may involve administration of a lower quantity of antivenom IgG that with a polyvalent antivenom. Several studies have shown, however, that this is not necessarily true [14,15]. Our results here demonstrated that the quality and neutralization capabilities of polyvalent antivenom are not necessary inferior to that of monovalent antivenoms. Here we compared the protein composition of the *N. kaouthia* monovalent antivenom (NKMAV) and Neuro Polyvalent Snake Antivenom (NPAV), as well as the in vitro neutralization potency of the two antivenoms against venoms from five common Asiatic cobras and *O. hannah* (Table 2). The results show that both antivenoms are devoid of high molecular weight aggregates, the compounds that are usually associated with adverse reactions. The protein contents of the two antivenoms are both relatively low (20.3 mg/mL and 12.5 mg/mL respectively, for NPAV and NKMAV). The neutralization potencies of NKMAV and NPAV against *N. kaouthia* (Thailand) venom (the venom used to raise both antivenoms) are essentially the same. This, however, is not surprising since according to the manufacturer, monovalent antivenoms (including NKMAV) were later added to the purified polyvalent antivenom to ensure the neutralizing potency of the NPAV was comparable with the neutralizing potencies of the respective monovalent antivenoms. What is interesting is that, the neutralization potencies of both antivenoms against four Asiatic cobra venoms tested are comparable. NPAV, however, is much more potent than NKMAV in neutralizing *O. hannah* venom. This is to be expected as *O. hannah* venom was included in the immunogen mixture used in raising NPAV. These observations are in accordance with the conclusion drawn by Raweerith and Ratanabanangkoon [15].
Neutralization potency of NPAV against venoms of Malaysian elapids

NPAV was raised using the four common elapid venoms in Thailand: *N. kaouthia* (Thailand), *O. hannah*, *B. candidus* and *B. fasciatus*. Our results showed that the polyvalent antivenom could effectively neutralize venoms of the same four species that originated from Malaysia. It is interesting that the polyvalent antivenom could effectively neutralize venom of *N. kaouthia* from Thailand too. According to Wüster and Thorpe [16], the composition of the venom of Thai *N. kaouthia* is substantially different from that of the Malaysian *N. kaouthia*, the former appears to be more neurotoxic, while the latter more nectrotic. It was suggested that this difference in the toxin composition may result in antivenom incompatibility. Our results, however, showed that while the two *N. kaouthia* venoms did differ substantially in their venom *i.e.* LD$_{50}$, the polyvalent antivenom that was raised from Thai *N. kaouthia* venom (together with other Thai elapid venoms) could effectively neutralize the venom of Malaysian *N. kaouthia*, albeit with a moderately lower ED$_{50}$. The same cross-neutralization potency was also observed with the monoclonal *N. kaouthia* antivenom.

In addition to the four elapid venoms mentioned, NPAV also effectively neutralized the venoms of the other Malaysian kraits *B. flaviceps* and *B. fasciatus*, as well as the medically important Equatorial spitting cobra *N. sumatrae*. Thus, the results of our in vivo neutralization studies suggest that NPAV, which is prepared from Thai elapid venoms, can be useful in the treatment of elapid envenoming in Malaysia, since the polyvalent antivenom can effectively neutralize venoms of all medically important elapids in Malaysia.

Neutralization potencies of NPAV against other Asiatic cobra venoms

Our results showed that NPAV was effective (P>0.5 mg/mL) against other Asiatic cobra venoms, including the venoms of the three Southeast Asian spitting cobras *N. siamensis*, *N. sumatrae* and *N. sputatrix*, as well as the venoms of the Central Asia cobra *N. oxiana* and Chinese cobra, *N. atra*. Earlier report claimed that Chinese cobra *N. atra* venom was poorly neutralized by other commercial cobra antivenoms [17]. NPAV, however, was only weakly effective against the venom of *N. philippinensis*, the highly neurotoxic (lethal) Philippine cobra. The low neutralization potency of 0.11 mg/mL would mean that more than 50 vials of NPAV may be required for the victim, as the amount of venom injected during a cobra bite can be more than 50 mg (dry weight). Indian polyvalent antivenom (raised from *N. naja* venom) has also been reported to show poor neutralizing ability against *N. philippinensis* venom.

NPAV was only moderately effective against *N. naja* venoms from the Indian subcontinent with the exception of one Sri Lankan *N. naja* venom sample (mixtures collected from several adult *N. naja*). The variation suggests geographical differences in *N. naja* venom.

Thus, our results suggest that NPAV is effective (P>0.5 mg/mL) in neutralizing the venoms of Asiatic cobras from Southeast Asia (except the Philippines cobra), Central Asia and China, but only moderately effective against venoms from the cobras from the Indian subcontinent. These observations can be used as the basis for the design of a polyvalent antivenom with a broader spectrum of cross-neutralization. For example, if venoms of *N. philippinensis*, *N. naja* and *B. caeruleus* were added to the immunogen mixture to raise NPAV, the resulting polyvalent antivenom may well be an effective Pan-Asian polyvalent cobra and krait antivenoms.

Neutralization potencies of NPAV against African cobra venoms

Five common African cobra venoms, including venoms from three spitting cobras (*N. nigricollis*, *N. nubie* and *N. katiensis*) were selected for this study. NPAV could neutralize effectively the venoms from *N. melanolouca*, but is moderately effective against that of the spitting cobras *N. nigricollis* and *N. nubie*, and weakly or not effective against venom of the highly lethal *N. haje* and the spitting cobra *N. katiensis*. We have not carried out a thorough study of the neutralization potency of NPAV against African cobra venoms, as many of the venoms are not available to us. Nevertheless, the results showed that there are still substantial cross-neutralizations between major venom toxins of the Asiatic and the African *Naja*, despite the fact that the Asian group lies in a more distant branch from the African group in the phylogenetic dendrogram [18].

Neutralization potency of NPAV against krait venoms

It is interesting to note that the NPAV could effectively neutralize the venoms of the three Southeast Asian kraits (*B. fasciatus*, *B. candidus* and *B. flaviceps*), but only moderately or weakly against the venoms of the other two kraits (*B. multicinctus* and *B. caeruleus*). The results indicate that krait venoms share enough common antigens among them to enable the NPAV raised against *B. fasciatus* and *B. candidus* to neutralize all 5 krait venoms tested. However, the low to moderate potency of NPAV against *B. multicinctus* and *B. caeruleus* venoms indicates significant differences in antigenicity of some of the venom toxins.

In vivo neutralization potency of NPAV versus in vitro neutralization potency

For all four elapid venoms tested, the i.m LD$_{50}$ values are comparable to the i.v. LD$_{50}$, indicating that the main venom toxins could diffuse effectively from muscle to circulation, presumably because these toxins are mainly low molecular weight proteins (phospholipases A$_2$ and the three-finger toxins). Also, the neutralization capability (as measured by ED$_{50}$) of NPAV in the in vivo assay is comparable to that of in vitro assay, suggesting that neutralization potential of antivenom against elapid snakes measured by the usual in vitro neutralization assay does provide a good indication of its effectiveness in the in vivo situation.

The protective effects of NPAV against cardiovascular depressant and neuromuscular blocking effects of *N. sputatrix* venom in anesthetised rats

To further examine the in vivo neutralization capability of the NPAV, we examined its ability to protect against *N. sputatrix* cobra venom-induced cardio-respiratory depressant and neuromuscular blocking effects in anesthetised rats. The antivenin (3 mL in total) was administered in 3 separate injections to minimize disturbing the cardio-respiratory parameters. It is well established that the major lethal toxins of *N. sputatrix* venom consist of polypeptide neurotoxins, polypeptide cardiotoxins and phospholipases A$_2$ [19]. The venom-induced cardio-respiratory depressant effect was likely due to the combined actions of polypeptide cardiotoxins and phospholipases A$_2$ whereas the neuromuscular blocking effect was likely due mainly to the action of the venom polypeptide neurotoxins, although venom phospholipases A$_2$ may also play a role. Thus, the ability of NPAV to effectively reverse the *N. sputatrix* venom-induced cardio-respiratory depressant and neuromuscular blocking effects in the rats demonstrated that the antivenin did contain specific antibodies that could effectively neutralize the major lethal toxins of *N. sputatrix* venom.
In conclusion, the in vitro and in vivo neutralization studies indicated that Neuro Polyvalent Snake Antivenom (NPAV) effectively neutralized venoms from many Southeast Asian Naja, Bungarus and Ophiophagus hannah but less effective against the venoms of Naja from the India subcontinent and Africa, as well as the Asiatic N. philippinensis. This cross-neutralization information can be used as the basis for the design of broader-spectrum polyvalent cobra antivenom. The abilities of NPAV to protect against N. sputatrix venom-induced cardio-respiratory depressant and neuromuscular blocking effects confirmed that the antivenom effectively neutralized the major lethal toxins of Naja venoms. The antivenom may find potential application in the treatment of elapid bites in Southeast Asia, especially Malaysia, a neighboring nation of Thailand. Nevertheless, the applicability of NPAV in the treatment of cobra and krait envenomations in Southeast Asia needs to be confirmed by clinical trials, as it is known that antivenom that has been proved effective in murine model is not necessarily effective in treating human victims [20].

Acknowledgments

The authors are grateful to Idaman Pharma for assisting in the import of the antivenoms, and to Queen Saovabha Memorial Institute for supplying the antivenoms.

Author Contributions

Conceived and designed the experiments: NHT SYF SMS. Performed the experiments: PKL. Analyzed the data: PKL NHT SYF SMS. Contributed reagents/materials/analysis tools: NHT KS VS. Wrote the paper: PKL NHT. Expert comments and advise on antivenoms: KS VS. Edited the manuscript: PKL SMS SYF KS VS NHT.

References

1. Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, et al. (2008) The global burden of snakebite: A literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 5: e218.
2. WHO (2010) Guidelines for the prevention and clinical management of snakebite in Africa. Brazzaville: WHO Regional Office for Africa.
3. Warrell DA (1995) Clinical toxicology of snakebite in Asia. In: Meier J, White J, eds. Handbook of clinical toxicology of animal venoms and poisons. Florida: CRC Press. pp 493–594.
4. O’dara M (2005) Venomous Snakes of the World. New Jersey: Princeton University Press.
5. Chipaux JP (2006) Snake venoms and envenomations. Florida: Krieger Publishing Company.
6. Warrell DA (2010) Guidelines for the management of snake-bite. WHO. 87 p.
7. Williams D (2011) Global Snake Bite Initiative News. International Society on Toxicology Newsletter. 59 p.
8. Howard-Jones N (1985) A CIOMS ethical code for animal experimentation. WHO Chose 39: 51–56.
9. Bradford MM (1976) Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
10. Studier FW (1973) Analysis of bacteriophage T7 early RNAs and proteins on slab gels. J Mol Biol 79: 237–248.
11. Ramos-Cerrillo B, de Roodi AR, Chipaux JP, Olguin L, Casasola A, et al. (2008) Characterization of a new polyvalent antivenom (Anticimpan® Africa) against African vipers and elapids. Toxicon 52: 681–688.
12. Morais V, Ifran S, Beraain P, Masauldi H (2010) Antivenoms: potency or median effective dose, which to use? Journal of Venomous Animals and Toxins including Tropical Diseases 16: 181–193.
13. Finney D (1952) Probit Analysis. Cambridge: Cambridge University Press.
14. Chipaux JP (2010) Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Biol Aujourdhui 204: 87–91.
15. Raweerith R, Ratanahabanglooen K (2005) Immunochemical and biochemical comparisons of equine monovalent and polyvalent snake antivenoms. Toxicon 45: 369–375.
16. Wüster W, Thorpe RS (1991) Asiatic cobras: systematics and snakebite. Experientia 47: 205–209.
17. Minton SA, Jr. (1967) Paraspecific protection by elapid and sea snake antivenins. Toxicon 5: 47–55.
18. Wüster W, Crookes S, Ineich I, Mané Y, Pook CE, et al. (2007) The phylogeny of cobras inferred from mitochondrial DNA sequences: Evolution of venom spitting and the phylogeography of the African spitting cobras (Serpentes: Elapidae: Naja nigricollis complex). Molecular Phylogenetics and Evolution 45: 437–453.
19. Tan NH, Arumugam A (1990) In vivo interactions between neurotoxin, cardiotoxin and phospholipases A2 isolated from Malayan cobra (Naja naja sputatrix) venom. Toxicon 28: 1193–1198.
20. Warrell DA, Warrell MJ, Edgar W, Prentice CR, Mathison J (1980) Comparison of Pasteur and Behringwerke antivenoms in envenoming by the carpet viper (Echis carinatus). Br Med J 280: 667–669.